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Wereportherethedesignandconstructionofseveralgenevectorsforexpressioninmammaliancellsofmembrane-boundandsol-
uble human T cell receptors (TR). We designed a vector (TR-ALPHA-IRES-TR-BETA pEF4) that encodes high-level expression of
the full-length TR on the surface of T cells. Furthermore, we engineered TR that does not require the presence of endogenous CD3
molecules for surface expression and thus expression is not limited to T cells. We also constructed a vector encoding a single-chain
TR (scTR) as a fusion protein of V-ALPHA-V-BETA-C-BETA with CD3Z. Since it is encoded and expressed as a single molecule,
this scTR is well suited for gene therapy. Lastly, we successfully used a mammalian expression vector for generation of soluble
human TR. The approaches we used here for manipulation of a human tumor-speciﬁc TR can be useful for other investigators
interested in TR-based immunotherapy.
Copyright © 2006 Nehad M. Alajez et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Failure of standard cancer therapies and their extreme tox-
icity have led to an increasing interest in utilizing the im-
mune system to ﬁght tumors. Adoptive transfer of in vitro
expandedtumor-inﬁltratinglymphocytes(TILs)inconjunc-
tion with high dose IL-2 to advanced melanoma patients re-
sulted in objective clinical responses [1]. Limitations for us-
ingadoptivetransferoftumor-reactiveTcellsrangefromthe
diﬃculty of obtaining suﬃcient numbers of TILs from most
cancer patients to the limited in vivo survival of adoptively
transferred T cells. To overcome these limitations several in-
vestigators have reported successful cloning of T cell receptor
alpha (TR-ALPHA) and T cell receptor beta (TR-BETA) se-
quences from tumor-reactive T cell clones and transduction
into in vitro activated primary T lymphocytes [2, 3].
Several reports in the literature have shown that func-
tional interaction between a T cell and its target is depen-
dent on the density and avidity of the TR for its ligand [4–8].
Therefore, for eﬀective immune therapy involving TR gene
transfer, it is necessary to design gene vectors that give the
highest level of surface expression of the TR. Many solutions
to speciﬁc problems involved in good TR expression from
gene vectors can be found in the literature, but each applies
to a diﬀerent TR recognizing a diﬀerent antigen. Thus, it has
been diﬃcult to directly compare speciﬁc solutions and to
deﬁne some universally applicable experimental approaches.
T h ep u r p o s eo fo u rs t u d yw a st od e s i g nd i ﬀerent constructs
andexpressionvectorsforoneTRspeciﬁcforthetumoranti-
gen MUC1 for potential use in cancer immunotherapy, and
to compare the level of cell surface TR expression achieved
through diﬀerent constructs on various cell types. In addi-
tion, we engineered and tested several constructs to obtain
a soluble form of the TR that could be used for therapeutic
purposes as well as to study the interaction between the TR
and its ligand. These vectors could be very useful tools for
investigators who are interested in studying TR function or
TR-based immunotherapy.
MATERIALS AND METHODS
Primers
Sequences of all primers (P1–P15) used for cloning and the
gene bank accession numbers for the correspondent genes
are listed in Table 1.2 Journal of Biomedicine and Biotechnology
Table 1: Nucleotide sequences and restriction enzyme cleavage.
Primer no Accession no Sequence
P1 DQ269212 5 -CGGGATCCTCGAGATGGAGACCCTCTTGGGCCTGCTTA-3 
P2 DQ269213 5 -CGGGATCCGTCGACATGGCCACCAGGCTCCTCTGCTG-3 
P3 DQ269212 5 -CGGGATCCGGAATTCTCAGCTGGACCACAGCCGCAGCGT-3 
P4 DQ269213 5 -ATAGTTTAGCGGCCGCGGATCCTCAGAAATCCTTTCTCTTGACCA-3 
P5 J04132 5 -GGGGATCCCAAACTCTGCTACCTGCTGG-3 
P6 J04132 5 TCCCCGCGGCGGCCGCGAATTCTTAGCGAGGGGGCAGGGCCTGCATG-3 
P7 DQ269212 5 -CGGGATCCAGATCCCCACAGGAACTTTCTGGGCTGGGGAAG-3 
P8 DQ269213 5 -CGGGATCCAGATCCCCACAGTCTGCTCTACCCCAGGCCTCG-3 
P9 DQ269213 5 -AGGCGCGCCCCCAGGCCTCGGCGCTGACGATC-3 
P10 BT019811 5 -AGGCGCGCCGACATGGCCCTGATTGTGCTGGGGGGC-3 
P11 BT019811 5 -AGGCGCGCCGACGCTGGGGATATGGCCCTGATTGTGCTGGG-3 
P12 DQ269213 5 CTAAGCGTAGTCTGGGACGTCGTATGGGTACAGATCCTCTT
CTGAGATGAGTTTTTGTTCTACAACGGTTAACCTGGTC-3 
P13 DQ269213 5 CCTGCAGGTCAATGGTGATGGTGATGATGCTTGTCATCG
TCATCCTTGTAGTCAGCGTCTGCTCTACCCCAGG-3 
P14 DQ269212 5 ATGTGGCTGCAGAGCCTGCTGCTCTTGGGCACTGTGGCC
TGCAGCATCTCTGCACCCCAGGAGGTGACGCAGATTC-3 
P15 DQ269212 5 CCATGGAGACAGACACACTCCTGCTATGGGTACTGCTG
CTCTGGGTTCCAGGTTCCACTGGTGACGCGGCCCAGGAGGTGACGCAGATTC-3 
Cloningoffull-lengthTR-ALPHAand
TR-BETAsequences
MA CTL clone, the source of the TR, was described before
[9]. RT-PCR was performed using GeneAmp RT-PCR kit
(Applied Biosystems, Foster City, Calif, USA) and using ei-
ther V-ALPHA (P1) or V-BETA (P2) leader sequence spe-
ciﬁc forward primers and C-ALPHA (P3) or C-BETA (P4)
reverse primers. The TR-ALPHA was cloned into the Xho I
and EcoR I sites in the multiple cloning site (MCS) A and
the TR-BETA was cloned into the Sal I and Not I sites in
MCS B in the pIRES vector (Clontech Laboratories, Palo
Alto, Calif, USA). The TR-ALPHA-IRES-TR-BETA cassette
was then subcloned into the pEF4 mammalian expression
vector (Invitrogen, Figure 1(a)).
Constructionofatwo-chainTcellreceptorand
asingle-chainTcellreceptorvectorsfor
expressiononTcellsandnon-Tcells
Human CD3Z chain was cloned using forward primer
(P5) and reverse primer (P6). This cloning strategy main-
tained an endogenous BamH I site at nucleotide number
80 in the extracellular domain of human CD3Z. PCR prod-
uct was cloned into the pCDNA3.1 TA vector (Invitro-
gen). The extracellular domains of the TR-ALPHA and TR-
BETA sequences were cloned using (P1) or (P2) forward
primers and (P7) or (P8) reverse primers, respectively. The
CD3Z/pCDNA3.1 vector was digested with BamH I restric-
tion enzyme (New England BioLabs, Beverly, Mass, USA)
and the TR-ALPHA or TR-BETA sequences were cloned in-
frame with the CD3Z chain at the BamH I site (Figures 2(a),
2(b)). The TR-ALPHA-Z and TR-BETA-Z were subcloned
into the pIRES vector at the Xho I/EcoR I and the Sal I/Not I
restrictionsites,respectively.FinallytheTR-ALPHA-Z-IRES-
TR-BETA-Z cassette was subcloned into the pLNCX2 (Clon-
tech)expressionvectorusingXhoIandNotIrestrictionsites
(Figure 2(c)). The scTR was constructed by cloning the TR
V-ALPHA and joining into the TR V-BETA-C-BETA (termi-
nating at 2nd-CYS) using ﬂexible linker (GGGGS)3.T h eT R
V-ALPHA-V-BETA-C-BETAwasthenligatedin-frametothe
murine CD3Z chain. A linker encoding a thrombin cleavage
site (GDLVPRGSSRLD) was introduced between the TR C-
BETA and the CD3Z transmembrane region. The scTR was
cloned into the pEF6 TA vector.
ConstructionofscTR-CD4TM-hZmammalian
expressionvectors
The scV-ALPHA-V-BETA-C-BETA was ampliﬁed using V-
ALPHA forward (P1) and C-BETA reverse (P9) primers and
cloned into the pEF6 TA vector. An Asc I site was intro-
duced at the C-terminus in the C-BETA region. The hu-
manCD4transmembrane(TM)domainfusedtothehuman
CD3Z cytoplasmic domain was ampliﬁed from the hCD4Z
vector (kindly provided by Dr Margo R. Roberts, Univer-
sity of Virginia, Va, USA) using forward (P10) and reverse
(P6) primers. Asc I and Sac II sites were introduced into the
forward and reverse primers, respectively, that allowed in-
frame ligation to the scTR extracellular domain. A modiﬁedNehad M. Alajez et al 3
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Figure 1: Expression of the TRAZ from MA CTL clone on the surface of a TR-deﬁcient Jurkat line (JRT3-T3.5). (a) The TR-ALPHA-IRES-
TR-BETA cassette was cloned into the pEF4 expression vector. (b) Untransfected JRT3-T3.5, (c) JRT3-T3.5 cells transfected with the TCRB
sequence, or (d) JRT3-T3.5 cells transfected with MA TR-ALPHA-IRES-TR-BETA pEF4 were stained with anti-CD3 Epsilon (open his-
togram) or with isotype control (ﬁlled histogram). IRES stands for internal ribosomal entry site. Zeocin is antibiotic resistance gene.
version of this vector was created by inserting three amino
acid (AGD) linker between the C-BETA region and the CD4
TM domain. In the latter, PCR was done using (P6) and
(P11) primers.
Surfacebiotinlabelingandthrombin
cleavageofscTR
Surface biotin labeling and thrombin cleavage was done as
previously described [10].
ConstructionofsecretedscTRs
Asoluble,single-chainfragmentvariable(scFv)encodingthe
TR V-ALPHA-V-BETA or soluble single-chain TR (soluble
scTR) domain consisting of the TR V-ALPHA-V-BETA-C-
BETA (terminated at 2nd-CYS) was cloned into pCDNA3.1
TAvectorbyRT-PCRusing(P1)and(P12)or(P2)and(P13)
primers, respectively. Modiﬁed versions of the soluble scTR
vector were created by fusing the sscTR to the GM-CSF, PCR
was done using P14 and P13, or Ig-κ light chain leader se-
quences (PCR was done using P15 and P13).
Celltransfection
Human embryonic kidney cells, HEK 293H, were trans-
fected using lipofectamine 2000 (Invitrogen) according to
manufacture’s instruction. Cells were analyzed for protein
expression 48–72 hours post-transfection. Jurkat cells were
electroporated using a BioRad Gene Pulser II (Bio-Rad Lab-
oratories, Hercules, Calif, USA) at 960μF and 200V settings.
Stimulationwithsuperantigen
BWZ and BWZ-scTR cells were stimulated with Staphylococ-
cus enterotoxin E (SEE) (Toxin Technology, Sarasota, Fla) as
described before [11]. Thirty-six hours later, IL-2 in culture
supernatant was measured using murine IL-2 ELISA kit (BD
PharMingen, San Diego, Calif) according to manufacture’s
recommendations.
PuriﬁcationofsolublescTRandwesternblotting
Transfected 293H cells were grown in DMEM-10. Seventy-
two hours after replacing with fresh medium, culture
m e d i u mw a sh a r v e s t e da n du s e df o rp r o t e i np u r i ﬁ c a t i o n .4 Journal of Biomedicine and Biotechnology
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Figure 2: Construction and expression of engineered MUC1-speciﬁc TRAZ and TRBZ receptors. Expression vectors for (a) TRAZ, (b) BZ, and
(c) AZ/BZ. (d) Untransfected 293H cells, (e) 293H cells cotransfected with the TRAZ and TRBZ, or (f) cells transfected with the AZ-IRES-
BZ pLNCX2 were stained for surface expression of the TR using anti-TR antibody BF1 (open histogram) or isotype control antibody (ﬁlled
histogram).
Anti-HA, c-Myc, and 6-His antibodies were purchased from
Santa Cruz Biotechnology, Santa Cruz, Calif, USA. Anti-
Flag M2 antibody was purchased from Sigma. For constructs
encoding c-Myc or HA tagged proteins, soluble scTR was
puriﬁed using protein G Sepharose beads (Amersham Bio-
sciences) coated with the appropriate anti-tag antibody. For
vectors encoding 6-His tagged proteins, soluble scTR was
puriﬁed using nickel-agarose column (Qiagen) according to
manufacture’s recommendations.
RESULTS
ReconstitutionoftheTR/CD3complexonthe
surfaceofJ.RT3-T3.5Jurkatlinetransfected
withtheTR-ALPHAandTR-BETAconstruct
J.RT3-T3.5 cells lack the TR-BETA transcript and have low
levels of the TR-ALPHA chain message, and are thus suit-
able host cells for testing expression of transfected TRs. The
pEF4 mammalian expression vector was chosen because ex-
pression of cloned genes is driven by the human elongation
factor-1 alpha (EF-1α) promoter, which is expected to be
more transcriptionally active and stable in T cells than viral
promoters. In addition, the presence of the IRES sequence
permits expression of the TR-ALPHA and TR-BETA genes
from the same message. This is expected to result in similar
levels of expression of both genes, in contrast to genes driven
by diﬀerent promoters. As shown in Figure 1, untransfected
JRT3-T3.5didnotexpresstheTR/CD3complexontheirsur-
face (Figure 1(a)). Transfection of the TR-BETA construct
alone did not reconstitute the TR/CD3 complex on cell sur-
face (Figure 1(b)); however, stable transfection of the TR-
ALPHA-IRES-TR-BETA pEF4 vector into J.RT3-T3.5 cells
resultedinhighlevelsofTR/CD3complexsurfaceexpression
(Figure 1(c)). Cells transfected with the TR-ALPHA-IRES-
TR-BETA pEF4 vector recognized MUC1+ tumors in vitro
{Alajez, 2005 [12]}.
EngineeredMUC1-speciﬁctwo-chainTRsallow
expressiononthesurfaceofnon-Tcells
The requirement for CD3 molecules for expression of the
TR on the cell surface limits its expression to T cells
only. We constructed engineered vectors that would by-
pass this requirement and allow expression of TR on
other cell types [10]. In T cells, the engineered vector
eliminates any possibility that the transferred TRs could
pair with endogenous TR-ALPHA or TR-BETA chainsNehad M. Alajez et al 5
that would reduce the level of the speciﬁc receptor on
t h es u r f a c ea sw e l la sf o r map o t e n t i a l l ya u t o r e a c t i v eT R
[13]. Construction of the TR-ALPHA-Z and TR-BETA-
Z was done as detailed in the “materials and methods.”
As shown in Figure 2, cotransfection of the TR-ALPHA-Z
Figure 2(a) and TR-BETA-Z Figure 2(b) constructs into hu-
man epithelial kidney HEK 293H (non-T cell) cells resulted
in surface expression of the TR-ALPHA-Z/TR-BETA-Z
heterodimer (Figures 2(d) and 2(e)). Similar level of surface
expression was also obtained when 293H cells were trans-
fected with the TR-ALPHA-Z-IRES-TR-BETA-Z pLNCX2
vector (Figures 2(c) and 2(f)).
Differentconﬁgurationsofsingle-chainTRs
wereexpressedatvariouslevels
onthesurfaceof293Hcells
For clinical application, transfection with multiple plas-
mids is a cumbersome procedure. Other groups had pre-
viously reported successful construction and expression of
single-chain TR (scTR) and single-chain antibodies [14, 15].
We made three diﬀerent MUC1 scTR constructs to com-
pare their eﬃciency by the levels of surface TR expres-
sion (Figure 3),scTR(showninFigure 3(b)),scTR-CD4TM-
hZ (shown in Figure 3(c)), and the scTR-AGD-CD4TM-hZ
(shown in Figure 3(d)). These scTRs consist of the TR anti-
gen binding domain and a signaling component from the
CD3Z chain. As shown in Figure 3(b), transfection of the
scTR into 293H cells resulted in a substantial increase in sur-
face expression compared to control (Figure 3(a))b u tt r a n s -
fection with the scTR-CD4TM-hZ construct gave a much
lower level of expression (Figure 3(c)). However, inserting
a 3-amino-acid (AGD) linker between the TR C-BETA and
the CD4 TM region restored high level of surface expres-
sion of the scTR (Figure 3(d)). It is possible that these 3
amino acids provided enough ﬂexibility to the scTR to al-
low proper folding of the molecule and normal level of sur-
face expression. Figure 3(e) shows the same results in a more
quantitativeway.HighsurfaceexpressionofthescTRwasde-
tected on both T cells (BWZ murine thymoma) and non-T
cells (rat basophilic leukemia (RBL)) transfected with scTR-
pEF6 vector (Figure 4(a)) .T h es c T Ri sf u n c t i o n a la ss h o w n
by the ability of the transfected BWZ cells to be stimulated
with plate-bound anti-TR BF1 antibody or with SEE super-
antigen, which binds speciﬁcally to the human TRB8 re-
gion (Figure 4(b)). These cells also recognized MUC1+ tu-
mor cells in vitro {Alajez, 2005 [12]}.
Multipleexpressionvectorsforsoluble
scTRproduction
Soluble (s) single-chain (sc) receptor (soluble scTR) could
be used as vehicles to deliver and target therapeutic drugs
to the site of their speciﬁc antigen (in our case a tumor
expressing MUC1), or it can be used to study the aﬃn-
ity of interaction between the TR and its ligand using Bi-
acore analysis. One approach we used to generate soluble
scTR was to introduce a thrombin cleavage site between the
scTR C-BETA domain and the CD3Z transmembrane re-
gion (Figure 5(a)). Figure 5(b) shows that the scTR contain-
ingthethrombincleavagesitecanbecleavedfromthesurface
of transfected cells. Following thrombin cleavage, the scTR
could be puriﬁed from the soluble fraction (Figure 5(c),l a n e
4)usinganaﬃnitycolumn.Asexpected,thesolublescTRhas
a lower molecular weight than the membrane-bound scTR
(Figure 5(c), lanes 2 and 4). The soluble scTR can be eluted
from the aﬃnity column under high pH elution conditions
(Figure 5(c), lane 8). Even though this approach was success-
ful in generating soluble scTR, the amount that was obtained
was extremely low. Other groups have reported expression
of a soluble, single-chain fragment variable (scFv) domain
of both antibody and T cell receptor [16, 17]. Figure 6(a)
shows the design of the soluble scFv construct that encodes
the TR V-ALPHA-V-BETA region. Figure 6(b) shows the
soluble scTR construct that was terminated just before the
2nd-CYS in the TR C-BETA region. Two other constructs
were designed as described in Figure 6(b), with the excep-
tion of replacing the V-ALPHA leader sequence in the sol-
uble scTR with either a GM-CSF (Figure 6(c))o rI g - κ light
chain (Figure 6(d)) signal peptide. Various epitope tags were
inserted at the C terminus to facilitate protein expression
and puriﬁcation. When the soluble scFv construct was trans-
fected into 293H cells, no recombinant soluble scFv protein
could be detected in the culture supernatant (Figure 6(e),
lane a ). However, transfection of the soluble scTR construct
into 293H cells resulted in signiﬁcant amounts of recombi-
nant protein secreted in culture supernatants (Figure 6(e),
lane b ). Transfection of the soluble scTR that was fused
to the Ig-κ light chain leader sequence gave a lower level
of protein expression than was seen in b  (Figure 6(e),l a n e
d ), and transfection of the soluble scTR construct fused to
the GM-CSF leader sequence yielded no protein secretion
(Figure 6(e),l a n ec  ). These results showed that the presence
of the TR C-BETA region is absolutely required for expres-
sion of the soluble scTR. We hypothesized that the TR C-
BETA region must be important for the proper folding of
the protein or it interacts with and masks other hydropho-
bic amino acid residues in the TR V-BETA region, otherwise
the scFv is rendered insoluble. As shown in Figure 6(f), the
recombinant soluble scTR could be puriﬁed from culture su-
pernatant using a nickel column. Figure 6(g) shows western
blot analysis of puriﬁed fractions obtained in Figure 6(f),u s -
ing anti-Flag M2 antibody. The expression o soluble form
scTR in these mammalian cells appears to be suﬃciently ro-
bust to produce this reagent for therapeutic purposes or for
biophysical analyses.
DISCUSSION
In this report, we adapted several mammalian expression
vectors for functional high-level expression of human TRA
and TRB chains that can be useful for biological or biochem-
ical analysis as well as immunotherapy. Our TRA-IRES-TRB
pEF4 vector encoding the tumor antigen-speciﬁc TR gener-
ated high levels and stable expression of the TRA/TRB/CD3
complex on the surface of transfected T cells. We also6 Journal of Biomedicine and Biotechnology
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Figure 3:ConstructionandexpressionofMUC1-speciﬁcsingle-chainTcellreceptors(scTRs).(a)293Hcellsweretransfectedwith(b)thescTR,
(c) scTR-CD4TM-hZ, or (d) scTR-CD4TM-AGD-hZ mammalian expression vectors. Cells were stained with anti-TR BF1 (open histogram)
or isotype control (ﬁlled histogram) antibody. (e) shows quantitative comparison of TR expression on 293H cells transfected with diﬀerent
scTR constructs. P<. 05.
engineered TRAZ and TRBZ that were successfullyexpressed
on the surface of 293H cells (a non-T cell line that does not
express the CD3 complex). Additionally, we showed that sur-
face expression of the TR was dependent on the coexpression
of the TRAZ and TRBZ (data not shown). We hypothesized
that pairing of the TRAZ to the TRBZ was crucial for proper
folding and transport of the heterodimer through the endo-
plasmic reticulum (ER) and Golgi and eventually to the cell
surface.
In contrast to the expression of two-chain TRs (tcTRs),
functional scTRs can be expressed on the cell surface from
a single mRNA transcript. In the example shown here weNehad M. Alajez et al 7
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Figure 4: Expression of functional scTR on the surface of T and non-T immune cells. (a) Rat basophilic leukemia (RBL) or BWZ cells were
transfected with the scTR-pEF6 and were stained for surface expression with anti-TR BF1 antibody (open) or with isotype control (ﬁlled)
histogram. (b) IL-2 secretion from BWZ cells (open bars) or BWZ-scTR (ﬁlled bars) following stimulated with SEE superantigen or with
anti-TR BF1 antibody. Stimulation with Ionomycin/PMA (I/P) served as the positive control.
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Figure 5: Expression and puriﬁcation of soluble scTR following surface biotin labeling and immunoprecipitation. (a) scTR expression vector
encoding a thrombin cleavage site, T. (b) RBL cells transfected with the scTR were stained with anti-TR BF1 antibody (open histograms)
before (right) or after (left) treatment with thrombin. Filled histogram shows staining with isotype control antibody. (c) Immunoprecipita-
tion of the scTR from RBL (lanes 1 and 3) or RBL cells transfected with the scTR (lanes 2 and 4) before (lanes 1 and 2) or after (lanes 3 and
4) treatment with thrombin. Lanes 6–8 are SA-HRP blotting of fraction eluted with 150mM Glycine, PH 2.2, 100mM Glycine PH 2.2, or
diethylamine (DEA) PH 11.2, respectively. Lane 5 is IP from control lysate.
constructed a single-chain TR speciﬁc for the tumor antigen
MUC1 and expressed it on the surface of diﬀerent cell types.
The expression of the scTR on the surface of transfected cells
waslowerthanthelevelofexpressionofthenativeTR,which
could be attributed to the presence of charged amino acids in
the transmembrane (TM) domain of the CD3Z chain that
might cause dimerization and retention of the scTR in the
endoplasmic reticulum. In an attempt to increase the level of
surface expression of the scTR, we replaced the TM domain
of CD3Z in the scTR with the TM domain of human CD4.8 Journal of Biomedicine and Biotechnology
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Figure 6:ExpressionandpuriﬁcationofsolublescTRusingmammalianexpressionsystem.(a)Thesingle-chainfractionvariable(scFv)domain
was cloned and fused to a C-terminus HA and c-myc epitope tags. (b) Secreted scTCR that was cloned and fused to a C-terminus Flag and
6-His epitope tags. (c) and (d) the secreted scTR as described in (b), with the exception that the secreted scTR was fused to the leader
sequence from GM-CSF (c) or from Ig-κ light chain (d). (e) Western blot of the culture supernatants from 293H cells transiently transfected
with constructs a–d (a –d ), immunoprecipitated with appropriate anti-tag antibody and blotted with anti-c-myc antibody (a ) or with anti-
Flag-M2 antibody (b –d ). Ctr is supernatant from untransfected cells. (f) Coomassie blue staining of fractions from culture supernatant
b  puriﬁed using nickel column. Lane 1 is culture supernatant before puriﬁcation, 2 is ﬂow through, 3 is wash, and 4–6 are diﬀerent eluted
fractions. (g) Western blot of panel (f) using anti-Flag M2 antibody.
However, this new construct was expressed at very low level
until we inserted a 3-amino-acid (AGD) linker between the
scTR constant region and the CD4 TM domain. High level
of surface expression of the scTR was restored in this new
construct. The short linker provided either ﬂexibility or suf-
ﬁcient spacing between the TR constant region and CD4 TM
to allow normal surface expression.
Most previous attempts to generate soluble TR were
made using prokaryotic expression systems. However, pro-
teins expressed in prokaryotic cells lack post-translational
modiﬁcations and may be improperly folded. In order to
avoid these potential problems, we chose to express soluble
MUC1-speciﬁc scTR using mammalian expression systems.
We terminated the scTR construct just before the last cystine
in the TR C-BETA region. Following transfection into 293H
cells, large amount of soluble scTR was detected in culture
supernatants.
In conclusion the various constructs we adapted and
tested for the expression of the MUC1-speciﬁc TR can be of
interest and help to other investigators interested in TR im-
munotherapy or in studying TR-antigen interactions.
ACKNOWLEDGMENTS
This work was supported by the NIH Grant CA56103 to O.
J. Finn and the DOD predoctoral training Grant DAMD17-
99-1-9352 to N. M. Alajez. We gratefully acknowledge the
contribution of Dr Mark Alter and Dr Jan Schmielau to the
early stages of this work.
REFERENCES
[1] Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regres-
sion and autoimmunity in patients after clonal repopulation
with antitumor lymphocytes. Science. 2002;298(5594):850–
854.
[2] Rubinstein MP, Kadima AN, Salem ML, et al. Transfer of
TCR genes into mature T cells is accompanied by the main-
tenance of parental T cell avidity. The Journal of Immunology.
2003;170(3):1209–1217.
[3] Morgan RA, Dudley ME, Yu YY, et al. High eﬃciency TCR
gene transfer into primary human lymphocytes aﬀords avid
recognition of melanoma tumor antigen glycoprotein 100 and
does not alter the recognition of autologous melanoma anti-
gens. The Journal of Immunology. 2003;171(6):3287–3295.
[4] Aarnoudse CA, Kr¨ use M, Konopitzky R, Brouwenstijn N,
Schrier PI. TCR reconstitution in Jurkat reporter cells facil-
itates the identiﬁcation of novel tumor antigens by cDNA
expression cloning. International Journal of Cancer. 2002;
99(1):7–13.
[5] Derby MA, Wang J, Margulies DH, Berzofsky JA. Two
intermediate-aviditycytotoxicTlymphocytecloneswithadis-
paritybetweenfunctionalavidityandMHCtetramerstaining.
International Immunology. 2001;13(6):817–824.
[6] Snyder JT, Alexander-Miller MA, Berzofsky JA, Belyakov IM.
Molecular mechanisms and biological signiﬁcance of CTL
avidity. Current HIV Research. 2003;1(3):287–294.Nehad M. Alajez et al 9
[7] Weijtens ME, Hart EH, Bolhuis RL. Functional balance be-
tween T cell chimeric receptor density and tumor associated
antigen density: CTL mediated cytolysis and lymphokine pro-
duction. Gene Therapy. 2000;7(1):35–42.
[8] Yang S, Linette GP, Longerich S, Haluska FG. Antimelanoma
activityofCTLgenerated fromperipheralbloodmononuclear
cells after stimulation with autologous dendritic cells pulsed
with melanoma gp100 peptide G209-2M is correlated to TCR
avidity. The Journal of Immunology. 2002;169(1):531–539.
[9] Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC, Finn
OJ. Intercellular and intracellular events following the MHC-
unrestricted TCR recognition of a tumor-speciﬁc peptide epi-
tope on the epithelial antigen MUC1. The Journal of Immunol-
ogy. 1998;160(7):3111–3120.
[10] Engel I, Ottenhoﬀ TH, Klausner RD. High-eﬃciency expres-
sion and solubilization of functional T cell antigen receptor
heterodimers. Science. 1992;256(5061):1318–1321.
[11] Mittelbrunn M, Y´ a˜ nez-M´ oM ,S a n c h oD ,U r s aA ,S ´ anchez-
Madrid F. Cutting edge: dynamic redistribution of tetraspanin
CD81 at the central zone of the immune synapse in both
T lymphocytes and APC. The Journal of Immunology. 2002;
169(12):6691–6695.
[12] Alajez NM, Schmielau J, Alter MD, Cascio M, Finn OJ. Thera-
peutic potential of a tumor-speciﬁc, MHC-unrestricted T-cell
receptor expressed on eﬀector cells of the innate and the adap-
tive immune system through bone marrow transduction and
immune reconstitution. Blood. 2005;105(12):4583–4589.
[13] Willemsen RA, Weijtens ME, Ronteltap C, et al. Grafting pri-
maryhumanTlymphocyteswithcancer-speciﬁcchimericsin-
gle chain and two chain TCR. Gene Therapy. 2000;7(16):1369–
1377.
[14] Novotny J, Ganju RK, Smiley ST, et al. A soluble, single-chain
T-cell receptor fragment endowed with antigen-combining
properties. Proceedings of the National Academy of Sciences of
the United States of America. 1991;88(19):8646–8650.
[15] Eshhar Z, Bach N, Fitzer-Attas CJ, et al. The T-body approach:
potential for cancer immunotherapy. Springer Seminars in Im-
munopathology. 1996;18(2):199–209.
[16] Gr´ egoire C, Lin SY, Mazza G, Rebai N, Luescher IF, Malis-
sen B. Covalent assembly of a soluble T cell receptor-peptide-
major histocompatibility class I complex. Proceedings of the
National Academy of Sciences of the United States of America.
1996;93(14):7184–7189.
[17] P a vlink ovaG,ColcherD ,BoothBJ ,GoelA,BatraSK.Pharma-
cokinetics and biodistribution of a light-chain-shuﬄed CC49
single-chain Fv antibody construct. Cancer Immunology, Im-
munotherapy. 2000;49(4-5):267–275.